Related Experiment Videos
Treatment of juvenile migraine with subcutaneous sumatriptan
1Minneapolis Clinic of Neurology, MN 55422.
Insights
Subcutaneous sumatriptan effectively treated severe migraine in children aged 6-16. Most experienced rapid headache relief and reduced symptoms, with mild side effects, indicating potential as a safe abortive therapy.
Area of Science:
- Pediatric Neurology
- Pharmacology
Background:
- Migraine is a common neurological disorder in children.
- Recurrent, severe migraine significantly impacts children's quality of life.
- Limited data exists on abortive migraine treatments for pediatric populations.
Purpose of the Study:
- To evaluate the efficacy and safety of subcutaneous sumatriptan for acute treatment of severe, recurrent migraine in children.
- To determine optimal dosing for pediatric patients.
Main Methods:
- An open-label, prospective study involving 17 children (ages 6–16) with severe migraine.
- Administration of either a 6-mg or 3-mg subcutaneous sumatriptan dose.
- Assessment of headache relief, associated symptoms, and side effects.
Main Results:
- 11 of 15 children achieved headache relief within 2 hours after a 6-mg dose.
- Both children receiving a 3-mg dose were headache-free within 2 hours.
- Significant improvement in nausea and photophobia was reported; side effects were mild and transient.
Conclusions:
- Subcutaneous sumatriptan demonstrates efficacy and safety as an abortive treatment for juvenile migraine.
- Further research is needed to establish precise dosing for smaller children.
Abstract:
An open, prospective study was undertaken to assess the efficacy and safety of subcutaneous sumatriptan in 17 children, ages 6 to 16 years, with severe, recurrent migraine. A 6-mg dose was used in 15 patients and relieved headache within 1 hour in six and by 2 hours in five others. Two smaller children received a 3-mg dose and both were headache-free within 2 hours. Most also reported marked improvement in associated symptoms such as nausea and photophobia. Four subjects had no clinical improvement after a 6-mg dose. Side effects, such as neck pressure, were brief and mild. These findings suggest that subcutaneous sumatriptan can be both effective and safe as an abortive agent in juvenile migraine, but the appropriate dose in smaller children will need further investigation.